Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Next Previous
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezafungin (Primary) ; Caspofungin; Fluconazole
  • Indications Candidaemia; Invasive candidiasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Cidara Therapeutics

    • Most Recent Events

    • 02 Feb 2024 According to a Napp Pharmaceuticals media release, company announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain. The authorisation was based on positive results from the pivotal ReSTORE Phase III clinical trial. The findings are supported by the STRIVE Phase II clinical trial and an extensive nonclinical development program.
    • 22 Dec 2023 According to a Cidara Therapeutics media release, REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults, based on results from ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials.
    • 05 Dec 2023 Results presented in the Melinta Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top